250 related articles for article (PubMed ID: 25146483)
21. Application of monoclonal antibodies for the identification of the antigenic site for poliovirus neutralization.
Minor PD; Schild GC; Evans D; Ferguson M; Almond J
Dev Biol Stand; 1984; 57():171-5. PubMed ID: 6084608
[TBL] [Abstract][Full Text] [Related]
22. Human monoclonal antibodies that neutralize vaccine and wild-type poliovirus strains.
Puligedda RD; Kouiavskaia D; Adekar SP; Sharma R; Devi Kattala C; Rezapkin G; Bidzhieva B; Dessain SK; Chumakov K
Antiviral Res; 2014 Aug; 108():36-43. PubMed ID: 24824031
[TBL] [Abstract][Full Text] [Related]
23. Potency of wild-type or sabin trivalent inactivated poliovirus vaccine, by enzyme-linked immunosorbent assay using monoclonal antibiotics specific for each antigenic site.
Sawyer LA; Wood D; Ferguson M; Crainic R; Beuvery EC; McInnis J; Albrecht P
Biologicals; 1997 Sep; 25(3):299-306. PubMed ID: 9324998
[TBL] [Abstract][Full Text] [Related]
24. Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccines.
Westdijk J; Brugmans D; Martin J; van't Oever A; Bakker WA; Levels L; Kersten G
Vaccine; 2011 Apr; 29(18):3390-7. PubMed ID: 21397718
[TBL] [Abstract][Full Text] [Related]
25. Crystal structure of a peptide complex of anti-influenza peptide antibody Fab 26/9. Comparison of two different antibodies bound to the same peptide antigen.
Churchill ME; Stura EA; Pinilla C; Appel JR; Houghten RA; Kono DH; Balderas RS; Fieser GG; Schulze-Gahmen U; Wilson IA
J Mol Biol; 1994 Aug; 241(4):534-56. PubMed ID: 7520084
[TBL] [Abstract][Full Text] [Related]
26. Antigenic analysis of poliovirus type 3 using monoclonal antibodies.
Ferguson M; Minor PD; Magrath DI; Schild GC
Dev Biol Stand; 1984; 57():151-5. PubMed ID: 6098495
[TBL] [Abstract][Full Text] [Related]
27. Localization and fine mapping of antigenic sites on the nucleocapsid protein N of porcine reproductive and respiratory syndrome virus with monoclonal antibodies.
Meulenberg JJ; van Nieuwstadt AP; van Essen-Zandbergen A; Bos-de Ruijter JN; Langeveld JP; Meloen RH
Virology; 1998 Dec; 252(1):106-14. PubMed ID: 9875321
[TBL] [Abstract][Full Text] [Related]
28. A cryo-electron microscopy study identifies the complete H16.V5 epitope and reveals global conformational changes initiated by binding of the neutralizing antibody fragment.
Lee H; Brendle SA; Bywaters SM; Guan J; Ashley RE; Yoder JD; Makhov AM; Conway JF; Christensen ND; Hafenstein S
J Virol; 2015 Jan; 89(2):1428-38. PubMed ID: 25392224
[TBL] [Abstract][Full Text] [Related]
29. Neutralizing antibody to human rhinovirus 14 penetrates the receptor-binding canyon.
Smith TJ; Chase ES; Schmidt TJ; Olson NH; Baker TS
Nature; 1996 Sep; 383(6598):350-4. PubMed ID: 8848050
[TBL] [Abstract][Full Text] [Related]
30. Different virus-precipitating activities of neutralizing monoclonal antibodies that recognize distinct sites of poliovirus particles.
Taniguchi K; Urasawa S
Arch Virol; 1987; 92(1-2):27-40. PubMed ID: 2432854
[TBL] [Abstract][Full Text] [Related]
31. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins.
Lok SM; Kostyuchenko V; Nybakken GE; Holdaway HA; Battisti AJ; Sukupolvi-Petty S; Sedlak D; Fremont DH; Chipman PR; Roehrig JT; Diamond MS; Kuhn RJ; Rossmann MG
Nat Struct Mol Biol; 2008 Mar; 15(3):312-7. PubMed ID: 18264114
[TBL] [Abstract][Full Text] [Related]
32. Structural studies on the folded domain of the human prion protein bound to the Fab fragment of the antibody POM1.
Baral PK; Wieland B; Swayampakula M; Polymenidou M; Rahman MH; Kav NN; Aguzzi A; James MN
Acta Crystallogr D Biol Crystallogr; 2012 Nov; 68(Pt 11):1501-12. PubMed ID: 23090399
[TBL] [Abstract][Full Text] [Related]
33. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus.
Gromowski GD; Barrett AD
Virology; 2007 Sep; 366(2):349-60. PubMed ID: 17719070
[TBL] [Abstract][Full Text] [Related]
34. Adeno-associated virus serotype 1 (AAV1)- and AAV5-antibody complex structures reveal evolutionary commonalities in parvovirus antigenic reactivity.
Tseng YS; Gurda BL; Chipman P; McKenna R; Afione S; Chiorini JA; Muzyczka N; Olson NH; Baker TS; Kleinschmidt J; Agbandje-McKenna M
J Virol; 2015 Feb; 89(3):1794-808. PubMed ID: 25410874
[TBL] [Abstract][Full Text] [Related]
35. [Antigen differences of genetic variants Abent+ and Abent- poliovirus vaccine strain of III type].
Shyrobokov VP; Kostenko IH; Nikolaienko IV
Mikrobiol Z; 2003; 65(4):29-36. PubMed ID: 14618784
[TBL] [Abstract][Full Text] [Related]
36. Structure of the major antigenic loop of foot-and-mouth disease virus complexed with a neutralizing antibody: direct involvement of the Arg-Gly-Asp motif in the interaction.
Verdaguer N; Mateu MG; Andreu D; Giralt E; Domingo E; Fita I
EMBO J; 1995 Apr; 14(8):1690-6. PubMed ID: 7537661
[TBL] [Abstract][Full Text] [Related]
37. Reverse engineering the antigenic architecture of the haemagglutinin from influenza H5N1 clade 1 and 2.2 viruses with fine epitope mapping using monoclonal antibodies.
Rockman S; Camuglia S; Vandenberg K; Ong C; Baker MA; Nation RL; Li J; Velkov T
Mol Immunol; 2013 Apr; 53(4):435-42. PubMed ID: 23127859
[TBL] [Abstract][Full Text] [Related]
38. Potential of mean force for Syrian hamster prion epitope protein--monoclonal fab 3f4 antibody interaction studies.
Wang YT; Su ZY; Liao JM; Chen CL
Eur J Med Chem; 2009 Sep; 44(9):3504-8. PubMed ID: 19304354
[TBL] [Abstract][Full Text] [Related]
39. Antigen chimaeras of poliovirus as potential new vaccines.
Burke KL; Dunn G; Ferguson M; Minor PD; Almond JW
Nature; 1988 Mar; 332(6159):81-2. PubMed ID: 2450279
[TBL] [Abstract][Full Text] [Related]
40. Use of monoclonal antibodies prepared with Sabin vaccine viruses for the characterization of poliovirus strains isolated in Canada.
Wachmann B; Henning D; Armstrong R; Boucher DW; Contreras G; Furesz J
Dev Biol Stand; 1984; 57():141-9. PubMed ID: 6084605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
